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Objectives. To evaluate, in children with Silver-Russell Syndrome, the response to the IGF-I and IGFBP-3 generation test and
compare results to the growth response after 6 months of rhGH. Methods. Eight children (6 males), with a mean age of 5.71±2.48
years and height SDS of −3.88 ± 1.28 received rhGH for 6 months. IGF-I and IGFBP-3 were analyzed before and after 4 doses of
rhGH. Results. The mean growth velocity (GV) before treatment was 5.28 ±1.9cm/year. GV increased after rhGH in ﬁve children
to a mean GV of 10.3±3.64cm/year. Six children had normal basal IGF-I levels and two low levels. After 4 doses of rhGH, the IGF-
I levels were normal in seven. There was no correlation between the growth response and the IGF-I generation test. Conclusions.
Children with SRS have normal IGF-I generation test. There is no correlation between the generation test and the growth velocity
after 6 months of rhGH.
1.Introduction
Silver-Russell syndrome (SRS) was ﬁrst described in 1953 by
Silver et al. [1]and in 1954 by Russell [2]. Ten percent of the
cases are due to maternal chromosome 7 disomy (mUPD7)
suggesting a genomic “imprinting” [3, 4]. In 2005 Gicquel
et al. [5] identiﬁed an epimutation (loss of methylation) of
the central telomeric imprinting center region 1 (ICR1) on
chromosome11p15invariouspatientswithtypicalSRSclin-
ical characteristics. Other authors subsequently conﬁrmed
the presence of these mutations with a high frequency (20–
63.8%) in patients with SRS [6]. This region is associated
with the regulation of many genes, such as tumor suppressor
genes (H19) and the IGF-2 gene. Hypermethylation in
this region is associated with Beckwith-Wiedemann syn-
drome characterized by excessive growth and/or asymmetry.
Hypomethylation in the H19/IGF2 region could lead to
asymmetry and fetal growth retardation as seen in SRS [7].
SRS and Beckwith-Wiedemann syndrome are currently con-
sidered two diseases caused by opposite epigenetic alteration
in the same chromosomal region (11p15) thus leading to
diﬀerent growth disorders [8–10]. This epigenetic defect can
be involved in syndromic intrauterine growth retardation
[5, 11]. The diagnosis is clinical and requires at least 3
of the following criteria: (1) birth weight 2 SDS or more
below the mean for gestational age (GA), (2) short stature
(height more than 2 SDS below the mean for children of
the same age and gender) at the time of the diagnosis, (3)
characteristic appearance (triangular face, small mandible,
low ear implantation, down turned corners of the mouth,
proeminent forehead), (4) clinodactyly of the 5th ﬁnger,
and (5) body asymmetry [12]. The incidence of SRS is 1
in 50.000 to 100.000 newborns [13], and it can be as high
as 1:3000 with a male predominance [14]. SRS diagnosis2 International Journal of Pediatric Endocrinology
although easily recognizable in extreme cases can be diﬃcult
in more subtle situations, especially in the absence of body
asymmetry.Intheirreviewofthepublisheddata,Netchineet
al. [10] recently proposed a clinical scoring system for diag-
nosis in those cases where the patient was born SGA. They
suggested that the patient must also have at least three of the
ﬁve following criteria: postnatal growth retardation, relative
macrocephaly, body asymmetry, prominent forehead, and
feeding diﬃculties, with a body mass index (BMI) < −2SD
during infancy and early childhood. The latter criterion was
included because it is particularly severe and frequent in
these children. They also stated that the scoring system is
highly predictive of a molecular defect in the diagnosis as
63.8% of patients here classiﬁed as SRS under this scoring
present 11p15 ICR1 epimutation (loss of methylation).
Many of these children do not present a postnatal catch-
up growth and show persistent short stature. The growth in
the ﬁrst three years of life is slow, and from this point on it
remains parallel to the curve but below the third percentile
[15]. Puberty may occur earlier than normal, and the growth
spurt can be smaller [16, 17]. The cumulative result of this
growth deﬁciency is short stature with an average adult
height of 151.2 ± 7.8cm for males and 139.9 ± 9.0cmfor
females, between –3.6 and –4.0 SD [15, 18].
GH treatment was approved in the United States in 2001
to be used in children with intrauterine growth retardation
(IUGR) (including SRS) who did not present a catch-up
growth until 2-3 years of age [19] and in Europe in 2003
after the age of 4 years. The initial age, the dose used, and the
height deﬁcit related to the parents height at the beginning
of the treatment are predictor factors of the growth response
[20–24]. These results were independent of the GH status
[23, 25–30]. Boguszewisk et al. [31] described abnormalities
in the 24-hour spontaneous GH secretion and lower levels
of IGF-I and IGFBP-3 demonstrating that although these
children do not present classical GH deﬁciency (GHD),
theirgrowthhormonesecretionisfrequentlyabnormal.Even
though the majority of these children achieve a normal adult
height when treatment is initiated early and is long lasting,
the response to rhGH therapy is heterogeneous.
Previous studies suggest that the IGF generation test can
be useful in the diagnosis of GH insensitivity syndrome
and in predicting their response to rhGH therapy. We raise
the question if in some cases of SRS the growth hormone
insensitivity could be inﬂuencing adult height and response
to rhGH.
The objectives of our study were to compare the growth
response after six months of rhGH to the response to the
IGF-I and IGFBP-3 generation test.
2. Methods
All SRS patients followed at the Instituto de Puericultura
e Pediatria Martag˜ ao Gesteira, the pediatric hospital of the
Universidade Federal do Rio de Janeiro, were evaluated. The
inclusion criteria were children clinically diagnosed with
SRS, older than 2 years, prepubertal, with a height more than
2 SD below the mean, bone age (BA) below 10 years, with
a minimum of 6 months of follow-up to calculate growth
velocity (GV), and never treated with rhGH. Children with
poor compliance with the regular visits or showing other
conditions that could aﬀect growth, like hypothyroidism,
were excluded.
This study was approved by the ethics committee of the
Universidade Federal do Rio de Janeiro. Informed consent
and child assent were obtained from parents or legal guardi-
ans and from the patients.
The diagnosis of SRS was established by an expert
geneticist based on the presence of at least 3 of the following
clinical criteria: (1) short stature; (2) weight and/or height at
birth below –2 SDS for gestational age [32]; (3) characteristic
facial features; [4] clinodactyly of the ﬁfth digit; (5) body
asymmetry.
In order to exclude the presence of other possible
conditions that could aﬀect growth or the IGF-I and IGFBP-
3 generation, a set of laboratories tests were performed in all
patients—complete blood count, erythrocyte sedimentation
rate,electrolytes,liverandkidneyfunctiontests,lipidproﬁle,
urine analysis, free thyroxine, and thyroid-stimulating hor-
mone.Magneticresonanceimaging(MRI)scanorcomputed
tomography (CT) of the brain and of the pituitary gland and
abdominal ultrasound were performed in all children. All
femalepatientshadakaryotypetoexcludeTurnersyndrome.
Serum samples were collected before the initiation of
rhGH and after 4 doses (in the morning of the ﬁfth
day). Immediately after collection, samples were centrifuged,
divided, and frozen at −20◦C. The IGF-I and IGFBP-3
analyses were performed at the same time. Serum levels
of IGF-I were analyzed by an IRMA assay (DSL, Webster,
TX) with an intra-assay coeﬃcient of variation of 3.4%
and interassay coeﬃcient of variation of 8.2%. The limit of
detection is 0,8ng/dL in a dilution of 1:30. Serum levels of
IGFBP-3 were analyzed by an IRMA assay (DSL, Webster,
TX) with an intra- and interassay coeﬃcient of variation
of 1.8% and 8.9%, respectively. The limit of detection is
0.0005mg/L.
Following the protocol described by Blum et al. [33], a
basal blood sample was collected, and all children received
subcutaneous rhGH (0.05mg/kg/day) daily for 4 doses. In
the morning of the ﬁfth day, another blood sample was
collected. An increment of 15ng/mL for IGF-I (IGF-I Δ)
and of 0.4mg/L for IGFBP-3 (IGFBP-3 Δ) was considered a
positive response to the generation test. After the generation
test, all patients continue to receive rhGH (same dose) for 6
months. Anthropometrical data collected at the beginning of
thegenerationtestsandafter6monthsofrhGHtherapywere
used to calculate the growth velocity.
Pre-and posttreatment bone age (BA) radiograph was




the protocol after the ﬁrst month and were excluded from
the study. The clinical characteristics of the eight remainingInternational Journal of Pediatric Endocrinology 3
patients are described on Table 1. Three children (patients
3, 4, and 8) showed body asymmetry. Two of them (3 and 4)
showedtheleftleglongerthantheright.Patient3asymmetry
was the more obvious one with the left leg 2cm longer than
the right one and the left foot 1cm longer than the right one.
3.2. Gestational and Delivery History. The gestational age
variedfrom36to40weekswitha mean ±SDof 38.25±1.75.
Justtwochildrenwerebornatlessthan37weeksofgestation.
The mean birth weight (±SD) was 1953.8g (±464.1). Six
of the patients were born with a weight more than 2 SD
below the mean. The mean birth length (±SD) was 41.88cm
(±3.27),and all of them had the birth length more than 2 SD
below the mean for gestational age. There was no uniform
history of teratogenic conditions.
3.3. Target Height. The fathers’ heights ranged from 165 to
189cm (–1.72 to 1.85 SDS) with a mean height of 178.3 ±
9.8cm and a mean height SDS of 0.23 ± 1.46. The mothers’
heights ranged from 156cm to 171cm, and the range of
maternal heights SDS was –1.29 to 0.55 with a mean height
SDS of −0.46 ± 0.96. One of the patients was adopted, and
no family information was available.
3.4. Growth Velocity (GV), Height SD Score and Bone Age Pre-
and Posttreatment. All 8 children were short with heights
SDS ranging from –6.53 to –2.5 (−3.88 ± 1.28). The mean
(±SD) bone age was 3.78 ± 2.85 years. All participants
were prepubertal throughout the study. The average growth
velocity (GV1) before treatment was 5.28 ± 1.9cm/year
Figure 1. Only two children had their growth velocity
pretreatment more than 2 SD below the mean.
After 6 months of treatment with rhGH, four patients
had a delta GH below 3cm/year Figure 1. The other 4
patients doubled their GV. Considering the height SDS, it
improved for at least 0.5 SD in half of the patients while the
other half had no change. The mean posttreatment growth
velocity (GV2) was 10.3±3.64cm/year, and the mean height
SDS after 6 months of treatment was −3.35 ±0.89.
3.5. IGF-I. Two children had basal serum levels of IGF-
I more than 2 SDS below the mean, and 6 had normal
basal levels. On the 5th day, serum IGF-I levels were normal
in 7 children and remained low in one child. The IGF-I
generation test was normal (delta >15ng/dl) in all children.
Figure 2 demonstrates the comparison between serum IGF-I
levels before and after 4 days of rhGH.
The greatest Δ IGF-I was observed in patient 1, and this
did not reﬂect the change in growth velocity as his growth
velocity remained unaltered with rhGH therapy.
Figure 3 demonstrates the correlation between the IGF-
I generation test and the change in growth velocity when
comparing the growth velocity before and after 6 months
of rhGH. Not only there was no correlation but the child
with the highest delta in IGF-I had the lowest change in
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Figure 3: Correlation between the IGF-I generation test and the
change in growth velocity.4 International Journal of Pediatric Endocrinology
Table 1: Clinical characteristics.
Gestational Birth Birth
Age Height Characteristic
Patient Gender Age Weight Length Asymmetry Clinodactyly
(year) (SDS) Facial features
(weeks) (g) (cm)
1M a l e 3 . 7 5 −3.44 40 2050 43 + − +
2M a l e 2 . 0 8 −2.5 40 2100 45 + − +
3F e m a l e 4 . 4 2 −3.38 39 1370 38 + + +
4M a l e 6 . 4 2 −2.7 40 2390 45 + + +
5M a l e 7 . 8 3 −4.71 36 1300 36 + − +
6M a l e 4 . 0 0 −4.08 36 1650 42 + − +
7M a l e 8 . 5 0 −3.67 37 2220 42 + − +



















Basal IGFBP-3 IGFBP-3 after 4 doses
Figure 4: IGFBP-3 values before and after 4 doses of rhGH.
3.6. IGFBP-3. One child had low basal serum levels of
IGFBP-3, two had normal serum levels, and 5 had basal
serum IGFBP-3 levels more than 2 SD above the mean. After
5 days of rhGH therapy, three children had normal serum
levels of IGFBP-3 and 5 had values more than 2 SD above
the mean. Four children had a positive IGFBP-3 generation
test (delta >0.4mg/L), and 4 had a negative test. Figure 4
demonstrates the comparison between serum IGFBP-3 levels
before and after 4 days of rhGH. There was no correlation
between the IGFBP-3 generation test and the change in
growth velocity. Even though the greatest change in IGFBP-3
was seen in the patient with the largest change in the growth
velocity (Figure 5), the second highest change in IGFBP-3
had one of the lowest changes in growth velocity.
3.7. Laboratories Parameters and Adverse Events. There were
no adverse events during rhGH therapy. Lower limb asym-
metry did not change during treatment.
4. Discussion
The number of patients in this study reﬂects the low inci-
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Figure 5: Correlation between the IGFBP-3 generation test and the
change in growth velocity.
The male gender is predominant in this study (6 boys)
as in the literature [35, 36] probably reﬂecting the predom-
inance of males in the referral to Pediatric Endocrinologists
due to short stature.
Among the facial characteristics, the small triangular
face with small mandible and prominent forehead (relative
macrocephaly) was evident in all children. Wollmann et al.
[18] analyzed data of 386 published patients and reported
that the small triangular facies is the most common charac-
teristic, present in 79% of patients.
Corporal asymmetry was detected in 1/3 of the patients.
The literature shows that body asymmetry has a frequency
between 33% to 51% [12, 15, 18]. This range can be partially
justiﬁed by the diﬃculty in detecting and quantifying
the asymmetry, especially in children with less manifested
phenotypes [35].
All patients had clinodactyly of the 5th ﬁnger similarly to
the published data (68%). One child had caf´ e au lait spots.
The published prevalence is around 19% [18].
Concerning birth data, 6 children were born with low
weight and all of them with their length more than 2SD
below the mean, similarly to published data [18].International Journal of Pediatric Endocrinology 5
Not all children with SRS respond well to rhGH therapy.
At the moment, most centers will administer rhGH and
evaluate the change in growth velocity after 6–12 months
to decide whether to continue or discontinue treatment. In
this study, we investigated if the short term (4 doses-5 days)
IGF-I and IGFBP-3 generation tests could predict the growth
response to 6 months of treatment with rhGH.
In this study the basal serum IGF-I was low in two chil-
dren (25%) while normal for the others (75%). Most studies
evaluating the growth response to rhGH in children with
SRS include them in studies investigating children with
intrauterine growth retardation (IUGR). Our data are in
contrast to Boguszewski’s et al. [20], who had shown IGF-I
and IGFBP-3 low levels in prepubertal children with IUGR.
InthestudiesbyThieriot-Prevostetal.[37]andBoguszewski
et al. [38], serum IGF-I levels increased in children who
had catch-up growth during the ﬁrst year of life, but not
in children without this catch-up growth. This statement is
not conﬁrmed in the ﬁndings here since serum levels of IGF-
I increased in all children, independently of the change in
growth velocity.
The used rhGH dose for the generation test was based
on the one used for children born SGA, since the SRS is
the extreme of IUGR. Buckway et al. [39] used 0.025 and
0.05mg/kg/day dose and observed little advantage of larger
rhGHdose.Blairetal.[40]didtestinidiopathicshortstature
(ISS) children using a standard dose (0.033mg/kg/day) and
low dose (0.011mg/kg/day) observing a better result with
the higher dose. From Stanhope et al. [41] and Albertsson-
Wikland et al. [42] studies was selected the use of a dose
of 0.05mg/kg/day as they postulated that the presence of
some resistance to GH action by children with SRS. The test
duration time was based in the literature, where the majority
was carried through in 4 days. Buckway et al. [43]a n dJ o r g e
et al. [44] found no advantage in more than 4-day test, as
there is no signiﬁcant diﬀerence in the increment and no
evidence that children with GHD or GHIS would show a
normal reply on more prolonged test.
In the present study serum levels of IGF-I increased more
than 15ng/mL in all children after rhGH, demonstrating
a non-GH resistant response. Regarding serum levels of
IGFBP-3, half of the patients did not increase serum levels by
more than 0.4mg/L, “failing” the generation test. When we
correlatedthegrowthresponsetothegenerationtestsresults,
there were no correlations, indicating that we cannot use the
short-term biochemical response to rhGH therapy to predict
the 6-month growth response.
One interesting patient to discuss is patient 8: she had
the lowest prestudy serum levels of IGF-I and IGFBP-3
(10ng/mL and 1.44mg/L, resp.) and the second lowest
prestudy growth velocity (4.5cm/year). When we look at her
response to 4 days of rhGH, her serum levels of IGF-I went
to 96ng/mL, and serum levels of IGFBP-3 went to 5.7mg/L.
After 6 months of rhGH, she had the highest annualized
growth velocity (16cm/year). These results suggest that she
could have GHD. The generation test was carried through
with no previous evaluation of GH deﬁciency since SGA
born children can show normal response to GH stimulation
tests even when they produce less GH than children with
a birth weight adequate for gestational age (AGA) or with
short stature [45–47].
Based on the results of our study, where not only there
was no correlation between the generation tests and the
growth response to rhGH therapy but also some of the more
robustresponsestooneofthetestswereassociatedwithsome
of the poorer responses to the other test, and vice versa,
we do not believe that increasing the number of patients
or increasing the length of follow-up would increase the
predictability of the test.
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